
Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce
Premium
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.
Conservative supporters of government deregulation want to do away with state-imposed licensing requirements, a move genetic counselors say will harm patients.
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
University of Helsinki Spinout Developing Blood Test to Tailor Treatment For High Cholesterol
Premium
Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can influence drug response.
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.